FMP

FMP

Enter

ARAV - Aravive, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ARAV.png

Aravive, Inc.

ARAV

NASDAQ

Inactive Equity

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

0.0401 USD

-0.0062 (-15.46%)

ARAV Financial Statements

Year

2022

2021

2020

2019

Total Revenue

9.14M

7.44M

5.68M

4.75M

Cost of Revenue

66.94M

37.54M

17.62M

12.84M

Gross Profit

-57.8M

-30.1M

-11.94M

-8.08M

Operating Expenses

79.97M

48.09M

30.68M

26.53M

Research and Development

66.94M

37.54M

17.62M

12.84M

Selling, General & Administrative Expenses

13.04M

10.55M

13.06M

13.69M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

13.04M

10.55M

13.06M

13.69M

Other Expenses

-5.49M

1.46M

-14k

2.53M

Operating Income

-70.84M

-40.65M

-30.78M

-21.77M

Total Other Income/Expenses Net

-5.49M

1.5M

241k

3.56M

Income Before Tax

-76.32M

-39.15M

-30.54M

-18.22M

Income Tax

4.6M

-1.01M

3.7M

2.04M

Net Income

-80.92M

-38.14M

-34.24M

-20.25M

Basic EPS

-2.22

-1.9

-2.17

-1.75

EPS Diluted

-2.22

-1.9

-2.17

-1.75

Basic Average Shares

36.37M

20.07M

15.79M

11.59M

Diluted Average Shares

36.37M

20.07M

15.79M

11.59M

EBITDA

-70.84M

-40.65M

-19.22M

-18.22M

Retained Earning Schedule

Year

2022

2021

2020

2019

Retained Earnings (Previous Year)

-539.8M

-500.65M

-470.11M

-450.56M

Net Income

-80.92M

-38.14M

-34.24M

-20.25M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-616.13M

-539.8M

-500.65M

-470.11M

Other Distributions

-76.32M

-39.15M

-30.54M

-19.55M

PPE Schedule

Year

2022

2021

2020

2019

Gross PPE

1.46M

2.21M

2.96M

8.7M

Annual Depreciation

886k

974k

11.57M

3.56M

Capital Expenditure

-11k

0

0

0

Net PPE

587k

1.23M

-8.61M

5.14M

Intangible and Goodwill Schedule

Year

2022

2021

2020

2019

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep